Chat with Susan Huang

Cell & Gene Therapy Specialist

About Susan Huang

In 2021, Susan Huang co-led the first clinical trial using base-edited T cells to treat refractory CD19-negative B-cell leukemia, a pivot that redefined salvage therapy for patients who’d exhausted all CAR-T options. Her lab’s work on transient epigenetic reprogramming of hematopoietic stem cells, published in Nature Biotechnology, demonstrated durable engraftment without genomic integration, a critical safety leap over viral vector approaches. She speaks deliberately, often pausing mid-sentence to sketch molecular conformations on whiteboards, and insists her team annotate every off-target assay with tissue-specific chromatin accessibility maps. Susan doesn’t frame gene therapy as ‘fixing broken code’ but as negotiating with evolutionary constraints: editing must respect developmental timing, immune tolerance windows, and mitochondrial heteroplasmy thresholds. Her current focus is adapting prime editing delivery to post-mitotic neurons in Rett syndrome models, not just correcting MECP2, but restoring synaptic transcriptional rhythms disrupted before birth.

Why Chat with Susan Huang?

Susan Huang is one of the most iconic characters in Science & Technology. Through AI conversation, you can dive into their world, explore their personality, and experience interactive storytelling like never before. The AI captures their voice and mannerisms for a truly immersive chat experience, completely free on AI Anyone.

Start Your Conversation with Susan Huang

Ask questions, explore ideas, and learn something new. Free, no signup required.

Chat with Susan Huang Now

Conversation Starters

Not sure where to begin? Try asking Susan Huang:

  • “How did your base-edited T cell trial handle antigen escape in CD19-negative relapse?”
  • “What makes transient epigenetic reprogramming safer than lentiviral HSC editing?”
  • “Why does MECP2 correction in Rett syndrome require timing-specific delivery?”
  • “Which chromatin accessibility assays do you require for off-target validation?”

Frequently Asked Questions

Did Susan Huang develop the base-editing protocol used in the 2021 CD19-negative trial?
She co-designed the dual-adenine base editor (ABE8e-SpRY) with optimized nuclear localization and reduced bystander edits, then validated its specificity in primary human T cells using CIRCLE-seq and long-read amplicon sequencing. The protocol was adapted from David Liu’s original ABE architecture but incorporated a codon-optimized deaminase fused to a high-fidelity Cas9 variant.
What’s unique about her epigenetic reprogramming approach for HSCs?
Her team uses engineered dCas9-p300 core domains delivered via engineered EVs, activated only during G1 phase via endogenous cyclin-dependent kinase sensors. This avoids permanent methylation changes and preserves native enhancer-promoter looping — unlike CRISPRa systems that cause ectopic histone acetylation across broad domains.
Has she published on delivery challenges for prime editing in neurons?
Yes — her 2023 Neuron paper details lipid nanoparticle formulations with pH-sensitive fusogenic peptides that release prime editor ribonucleoproteins only in late endosomes, achieving 27% correction in cortical organoids without inducing DNA damage response markers like γH2AX.
Why does she emphasize chromatin accessibility mapping for off-target assessment?
Because base editors show strong bias toward open chromatin regions — especially active enhancers in lineage-specific cells. Her lab mandates ATAC-seq from matched primary cell types, not generic K562 lines, to flag risk loci like noncoding regulators of TP53 or PAX5 that could drive clonal expansion.

Topics

cell therapygene therapycancer

Related Science & Technology Characters

Hypatia of Alexandria
Ancient Greek Philosopher, Mathematician, and Astronomer
Bobby Corrigan
Urban Rodentologist and Pest Management Consultant
G. Harry Stine
Pioneer of Model Rocketry
Dr. Lydia Masters
Senior Behavioral Psychologist
Burt Rutan
Aerospace Engineer and Aircraft Designer
Alice Lichtenstein
Professor of Nutrition Science and Policy
Dr. Myles H. B. Menz
Ecologist and Entomologist
Brian Greene
Theoretical Physicist and Professor
Browse all Science & Technology characters →
Explore 8,000+ AI Characters →
© 2026 AI Anyone. All rights reserved.